We can readily understand why investors are attracted to unprofitable companies. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring ...

If you own shares in Camurus AB (publ) (STO:CAMX) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure of volatility. Modern ...

Eli Lilly is counting on Camurus and its long-acting delivery technology to help take its portfolio of obesity and diabetes drugs to the next level with a licensing deal worth up to $870 million. With ...

On Tuesday, Camurus (OTC:CAMRF) and Eli Lilly and Company (NYSE:LLY) entered into a collaboration and license agreement. This agreement grants Lilly exclusive, worldwide rights to research, develop, ...

Eli Lilly and Camurus have entered into partnership worth up to $870m to develop long-acting therapies in cardiometabolic health. The collaboration and licence agreement gives Lilly exclusive global ...

Eli Lilly’s engineered peptide drugs Mounjaro and Zepbound are once-weekly injectable products, formulations that are expensive to manufacture and burdensome to patients who dislike needles. Lilly ...

LUND, Sweden, July 1, 2025 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the European Commission (EC) has granted Oczyesa®, octreotide subcutaneous depot, marketing authorization* ...

"Q1 performance on track for full-year guidance" Summary first quarter 2026 January - March Total revenues decreased 5% (increased 3% at CER1) to SEK 533 (558) million Product sales decreased 12% ...

The simplest way to invest in stocks is to buy exchange traded funds. But one can do better than that by picking better than average stocks (as part of a diversified portfolio). For example, the ...

New data support long-term safety and efficacy of weekly and monthly subcutaneous buprenorphine depots in patients with opioid use disorder Camurus (NASDAQ STO: CAMX) and Braeburn Pharmaceuticals ...

LUND, Sweden, May 24, 2023 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announces that the US Food and Drug Administration (FDA) has approved Brixadi™ (buprenorphine) extended release injection ...